Metisene [DCIT] en es it fr

Metisene [DCIT] Brand names, Metisene [DCIT] Analogs

Metisene [DCIT] Brand Names Mixture

  • No information avaliable

Metisene [DCIT] Chemical_Formula


Metisene [DCIT] RX_link

Metisene [DCIT] fda sheet

Metisene_[DCIT] FDA

Metisene [DCIT] msds (material safety sheet)

Metisene [DCIT] Synthesis Reference

No information avaliable

Metisene [DCIT] Molecular Weight

365.835 g/mol

Metisene [DCIT] Melting Point

256 oC

Metisene [DCIT] H2O Solubility

60.3 mg/L

Metisene [DCIT] State


Metisene [DCIT] LogP


Metisene [DCIT] Dosage Forms

Tablet for oral administration (0.5mg)

Metisene [DCIT] Indication

For the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class.

Metisene [DCIT] Pharmacology

Metolazone is a quinazoline diuretic, with properties generally similar to the thiazide diuretics. A proximal action of metolazone has been shown in humans by increased excretion of phosphate and magnesium ions and by a markedly increased fractional excretion of sodium in patients with severely compromised glomerular filtration. This action has been demonstrated in animals by micropuncture studies.

Metisene [DCIT] Absorption

Peak blood levels are obtained within 2 to 4 hours of oral administration.

Metisene [DCIT] side effects and Toxicity

Symptoms of overdose include difficulty breathing, dizziness, dizziness on standing up, drowsiness, fainting, irritation of the stomach and intestines, and lethargy leading to coma.

Metisene [DCIT] Patient Information

No information avaliable

Metisene [DCIT] Organisms Affected

Humans and other mammals